| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, Harvard Medical School, Boston, Massachusetts 02115
We have previously characterized specific binding of the phorbol ester tumor promoter [20-3H]phorbol 12,13-dibutyrate to several tissues, including mouse skin and brain. We report here that specific binding activity in chicken brain increases dramatically during development. In whole embryonic chicken brain, binding increased from 2.0 to 6.8 to 10.6 pmol/mg of protein at 7, 14, and 20 days, respectively. Adult chicken brain bound 15 pmol/mg of protein. In contrast to specific binding activity, binding affinity remained constant. Substantial regional localization of binding activity within the brain was found. For calf brain, representative values ranged from 4.6 pmol/mg for medulla to 38.1 pmol/mg for frontal lobe. Binding affinity did not vary. Inhibition of binding by postulated neurotransmitters and antagonists was examined. D-Propranolol and quinidine, membrane-stabilizing drugs, inhibited binding competitively, although at mM concentrations.
1 Supported by Grant CA22895 from the NIH.
2 Fellow of the Interdisciplinary Programs in Health, Harvard School of Public Health.
3 Exchange scientist under the United States-France Cancer Program, sponsored by the National Cancer Institute and INSERM. Present address: Centre National de la Recherche Scientifique, 7, Rue Guy-Mocquet, 94800 Villejuif, France.
4 Recipient of a Research Career Development Award from the NIH. To whom requests for reprints should be addressed.
Received 4/14/80. Accepted 9/26/80.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |